Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other prod… Read more
Onconetix Inc (ONCO) - Net Assets
Latest net assets as of September 2025: $3.38 Million USD
Based on the latest financial reports, Onconetix Inc (ONCO) has net assets worth $3.38 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.68 Million) and total liabilities ($16.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.38 Million |
| % of Total Assets | 17.15% |
| Annual Growth Rate | 9.88% |
| 5-Year Change | 103.02% |
| 10-Year Change | N/A |
| Growth Volatility | 594.7 |
Onconetix Inc - Net Assets Trend (2019–2024)
This chart illustrates how Onconetix Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Onconetix Inc (2019–2024)
The table below shows the annual net assets of Onconetix Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $9.61 Million | +584.28% |
| 2023-12-31 | $1.40 Million | -93.73% |
| 2022-12-31 | $22.39 Million | +1447.65% |
| 2021-12-31 | $1.45 Million | -69.44% |
| 2020-12-31 | $4.73 Million | -21.08% |
| 2019-12-31 | $6.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Onconetix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11474375100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $118.00 | 0.00% |
| Other Comprehensive Income | $-2.72 Million | -28.34% |
| Other Components | $128.02 Million | 1332.05% |
| Total Equity | $9.61 Million | 100.00% |
Onconetix Inc Competitors by Market Cap
The table below lists competitors of Onconetix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dong-A Socio Holdings Co. Ltd.
KQ:000640
|
$657.87K |
|
HOLOGIC - Dusseldorf Stock Exchang
DU:HO1
|
$658.04K |
|
Safeture AB
ST:SFTR
|
$658.21K |
|
Juno Minerals Ltd
PINK:JNOMF
|
$659.23K |
|
FLSMIDTH & CO. - Dusseldorf Stock Exchang
DU:F6O1
|
$657.40K |
|
BACHEM HLDG N -B-
MU:BHM
|
$657.38K |
|
Earthworks Industries Inc
PINK:EAATF
|
$657.30K |
|
Tancheng Group Co., Ltd.
PINK:QSJC
|
$657.23K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Onconetix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -5,602,028 to 9,610,555, a change of 15,212,583.
- Net loss of 58,691,023 reduced equity.
- Dividend payments of 206,404 reduced retained earnings.
- Share repurchases of 718 reduced equity.
- New share issuances of 3,483,031 increased equity.
- Other comprehensive income decreased equity by 5,104,317.
- Other factors increased equity by 75,732,014.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-58.69 Million | -610.69% |
| Dividends Paid | $206.40K | -2.15% |
| Share Repurchases | $718.00 | -0.01% |
| Share Issuances | $3.48 Million | +36.24% |
| Other Comprehensive Income | $-5.10 Million | -53.11% |
| Other Changes | $75.73 Million | +788.01% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Onconetix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1846.23 | $0.52 | x |
| 2020-12-31 | $1456.99 | $0.52 | x |
| 2021-12-31 | $445.24 | $0.52 | x |
| 2022-12-31 | $6203.38 | $0.52 | x |
| 2023-12-31 | $-1113.28 | $0.52 | x |
| 2024-12-31 | $297.54 | $0.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Onconetix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -610.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2325.21%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 2.93x
- Recent ROE (-610.69%) is below the historical average (-159.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -13.70% | 0.00% | 0.00x | 1.01x | $-1.42 Million |
| 2020 | -33.79% | 0.00% | 0.00x | 1.02x | $-2.07 Million |
| 2021 | -236.24% | 0.00% | 0.00x | 2.13x | $-3.56 Million |
| 2022 | -59.94% | 0.00% | 0.00x | 1.18x | $-15.66 Million |
| 2023 | 0.00% | -63986.48% | 0.00x | 0.00x | $-36.85 Million |
| 2024 | -610.69% | -2325.21% | 0.09x | 2.93x | $-59.65 Million |
Industry Comparison
This section compares Onconetix Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Onconetix Inc (ONCO) | $3.38 Million | -13.70% | 4.83x | $657.63K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |